Connect your AI

Sutro Biopharma STRO Stock-Based Comp

Stock-Based Comp at other companies

PfizerPFE

$272M+60.0%

Gilead SciencesGILD

$218M+4.3%

RegenxbioRGNX

$8.62M+0.9%

Nuvectis Pharma, Inc.NVCT

$1.85M+35.2%

XencorXNCR

$9.56M-21.7%

AnaptysBio, Inc.ANAB

$14.22M+55.0%

Other financials

Income statement

Revenue$14.5M-16.5%

Operating income-$29.7M+56.7%

Net income-$38.5M+49.3%

EPS (diluted)-$2.94+67.6%

Balance sheet

Cash & equivalents$73.7M-30.6%

Total debt$13.6M-36.3%

Total equity-$66.9M-159%

Total assets$242.0M-24.7%

Cash flow

Operating cash flow-$42.3M+37.7%

CapEx--100%

Free cash flow-$42.3M+37.8%

Valuation

Market cap$489.66M+624%

Enterprise value$429.61M-2,600%

P/S4.9×+3.9×

Profitability

Operating margin-120%-48.6pp

Net margin-154.2%-56.7pp

FCF margin-152.2%-51.1pp

Returns & leverage

Return on equity-234.2%—

Debt / equity0.5×+0.3×

Current ratio3.1×+1.0×

Where this comes from

Reported directly by Sutro Biopharma in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Sutro Biopharma’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sutro Biopharma's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Sutro Biopharma's stock-based comp?: Sutro Biopharma (STRO) reported stock-based comp of $1.56M in Q1 2026.
How has Sutro Biopharma's stock-based comp changed year-over-year?: Sutro Biopharma's stock-based comp decreased by 71.8% year-over-year, from $5.54M to $1.56M.
What is the long-term trend for Sutro Biopharma's stock-based comp?: Over 4 years (2021 to 2025), Sutro Biopharma's stock-based comp has grown at a -11.9% compound annual growth rate (CAGR), from $23.24M to $14.01M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.